Search
for
Sort by
Research 30 of 1000+
- Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Management of Toxicities of Targeted Therapies
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Hypertrichosis of the pinnae in a patient using panitumumab
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- SPRY1 Deficiency in Keratinocytes Induces Follicular Melanocyte Stem Cell Migration to the Epidermis through p53/Stem Cell Factor/C-KIT Signaling
- Drug-induced scarring and permanent alopecia
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Lrig1-expression confers suppressive function to CD4+ cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis
- Amphiregulin in Fibrotic Diseases and Cancer
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- Cutaneous drug reactions
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Hair growth stimulated by conditioned medium of adipose-derived stem cells is enhanced by hypoxia: evidence of increased growth factor secretion
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Potential Use of Spin Traps to Control ROS in Antipollution Cosmetics—A Review